Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 5Phase 1 3Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Completed 21Terminated 9Unknown 4Active not recruiting 4Withdrawn 2Not yet recruiting 2Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Radiotherapy, Intensity-Modulated × Clear all
NCT03991104 2023-09-21

SOX-based CRT for Esophageal Cancer.

Zhejiang Provincial People's Hospital

Phase 1/2 Withdrawn
Gastrointestinal

Esophageal Neoplasms

NCT01079793 2020-08-20

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

University of Texas Southwestern Medical Center

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡